<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-ZY2RXUT3</identifier><date>2019</date><creator>Makovec, Tomaž</creator><relation>documents/doc/Z/URN_NBN_SI_doc-ZY2RXUT3_001.pdf</relation><relation>documents/doc/Z/URN_NBN_SI_doc-ZY2RXUT3_001.txt</relation><format format_type="issue">2</format><format format_type="volume">53</format><format format_type="type">article</format><format format_type="extent">str. 148-158, I</format><identifier identifier_type="ISSN">1318-2099</identifier><identifier identifier_type="COBISSID">35773699</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-ZY2RXUT3</identifier><language>eng</language><publisher>Association of Radiology and Oncology</publisher><source>Radiology and oncology (Ljubljana)</source><rights>BY</rights><subject language_type_id="slv">cisplatin</subject><subject language_type_id="slv">kemoterapija</subject><subject language_type_id="slv">molekularni mehanizem</subject><subject language_type_id="slv">rak (medicina)</subject><subject language_type_id="slv">rezistenca</subject><title>Cisplatin and beyond</title><title>molecular mechanisms of action and drug resistance development cancer chemotherapy</title></Record>